paclitaxel

After irradiation to the pain area, paclitaxel and bevacizumab therapy was administered, and a marked reduction of pulmonary and liver metastases, and the disappearance of pain were observed. Local hepatic therapy with TAE followed by chemotherapy was thought to have helped the patient overcome the rapid tumor growth.

Postoperatively, tamoxifen, a CDK4/6 inhibitor, and radiotherapy were administered...Despite initiating weekly paclitaxel plus bevacizumab, the disease progressed rapidly, and she died 4 months later. Notably, OMS symptoms did not recur. This case highlights paraneoplastic OMS as an initial manifestation of breast cancer, with neurological improvement following systemic therapy.

Following completion of weekly paclitaxel(PTX), initiation of epirubicin plus cyclophosphamide(EC)resulted in a marked platelet decrease to 1.3×104/μL on day 7, necessitating repeated platelet transfusions. These findings suggest that in breast cancer patients with ITP, neoadjuvant chemotherapy may not be feasible, and primary surgical intervention should be considered. Furthermore, when administering EC, vigilant hematological monitoring is imperative.

Because of HER2 negative, 2 courses of ramucirumab plus paclitaxel was administered, but lung metastasis, increased liver metastasis, and ascites were detected...Nivolumab treatment was continued, and there has been no further disease progression at 83 months post-surgery. This case shows that disease control was achieved with nivolumab for liver, lung, and lymph node metastases following gastric cancer surgery, and long-term survival was attained with multimodal therapy.

P3, N=1100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P2, N=90, Not yet recruiting, University of Chicago

In a murine MRSA pneumonia model, PTX-trained mice showed reduced bacterial burden, preserved lung barrier integrity, and enhanced immune activation, all of which were reversed by GPR183 inhibition or STING deficiency. Collectively, our findings uncover a previously unrecognized immunomodulatory function of PTX and highlight the therapeutic potential of targeting the GPR183-STING axis to enhance trained immunity against resistant bacterial infections.

Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate (ADC) composed of the DM4 payload conjugated to a folate receptor α (FRα)-targeting antibody via the cleavable sulfo-SPDB linker. The MIRV Phase 3 registrational trial (MIRASOL) showed superiority of MIRV vs. chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) in patients with high (≥ 75%) FRα-expression PROC, showing an objective response rate of 42% versus 16%, a median progression-free survival of 5.6 versus 4.0 months, and an overall survival of 16.5 versus 12.8 months. Here, we briefly review MIRV mechanism of action, pharmacokinetics, pharmacodynamics, and key clinical efficacy and safety data.

P3, N=640, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting

Together, our data suggest that impairment in mitochondrial dynamics of sensory neurons contributes to paclitaxel neurotoxicity and, consequently, to nociception. Therefore, preventing mitochondrial fission may be a strategy to prevent PTX-induced neurotoxicity, opening a new perspective to understanding the mechanisms involved in the development of PTX-induced neuropathy.

P2, N=116, Not yet recruiting, Yonsei University

A decrease in their number worsens pain intensity, possibly by altering the CD4⁺/CD8⁺ T cell balance. In contrast, NK cell reductions in T cell-deficient rats may contribute to hypersensitivity in the absence of T cells.